Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses

Conclusions Cost-effective strategies were: ESG for class I obesity and SG for class II/III obesity. Semaglutide may be cost-effective with substantial cost reduction. Given potentially higher utilisation rates with pharmacotherapy, semaglutide may provide the largest reduction in obesity-related mortality.

http://gut.bmj.com/cgi/content/short/72/12/2250?rss=1

Source: Gut - November 24, 2023 Category: Gastroenterology Authors: Saumoy, M., Gandhi, D., Buller, S., Patel, S., Schneider, Y., Cote, G., Kochman, M. L., Thiruvengadam, N. R., Sharaiha, R. Z. Tags: Gut Obesity Source Type: research

More News: Eating Disorders & Weight Management | Gastrectomy | Gastroenterology | Obesity | Weight Loss